Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259035 · ClinicalTrials.gov registry record · Phase 2
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
A Phase 2 study, sponsored by Canadian Cancer Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03259035: Completed Phase 2 study, sponsored by Canadian Cancer Trials Group.
NCT03259035 is a Phase 2 study that has completed, run by Canadian Cancer Trials Group. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259035, a Phase 2 study, has completed, sponsored by Canadian Cancer Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
Primary Outcome
Defined as the percentage of patients with tumour downstaging to ypT0/T1good N0 and who avoid radical surgery.
Interventions
- DRUG Capox
- DRUG Folfox Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
What the finished NCT03259035 record still lists
NCT03259035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Capox is the first listed.
NCT03259035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259035 about?
NCT03259035 is a clinical study titled "NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer". The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
What is the current status of trial NCT03259035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-06-29. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT03259035?
The interventions under investigation include: Capox (DRUG), Folfox Protocol (DRUG).
Who is sponsoring clinical trial NCT03259035?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259035's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI